title: Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
abstract: BACKGROUND
  The prognosis of patients with systemic light chain (AL) amyloidosis, particularly cardiac, is poor. Treatments have been derived from multiple myeloma, but there are few studies that use triplet regimens in AL amyloidosis because of concern of greater toxicity than seen in myeloma.
  
  
  METHODS
  We conducted a retrospective review of patients with newly diagnosed AL amyloidosis who were initially treated with a triplet regimen.
  
  
  RESULTS
  For the 9 patients included, the median age was 64 years, and 8 were ineligible for stem cell transplantation. At least 2 organs were involved in 4 patients, including 7 with kidney and 4 with heart involvement, 2 of whom had New York Heart Association class 3 heart failure. All the patients received bortezomib, cyclophosphamide or lenalidomide/thalidomide, and dexamethasone. With a median follow-up of 13 months, 8 of 9 patients had a hematologic response, including 2 who achieved complete response, with a median time to response of 2.7 months. An organ response was seen in 7 of 9 patients, including all 4 patients with cardiac involvement. There were no deaths, and only 1 patient had progressive disease. The major toxicity observed was fluid overload and syncope, seen only in patients with heart failure, who eventually achieved a partial or complete response.
  
  
  CONCLUSIONS
  Dose-attenuated triplet regimens achieved rapid hematologic responses with manageable and reversible toxicity in patients with newly diagnosed AL amyloidosis.
authors.affiliation: Division of Hematology and Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA. ajai.chari@mountsinai.org
authors.forename: Ajai
authors.initials: A
authors.lastname: Chari
authors.forename: Kevin
authors.initials: K
authors.lastname: Barley
authors.forename: Sundar
authors.initials: S
authors.lastname: Jagannath
authors.forename: Keren
authors.initials: K
authors.lastname: Osman
mesh_terms: D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003520:Cyclophosphamide; D000077269:Lenalidomide